Allosensitization

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Allosensitization trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT01999361

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide…

United States18 participantsStarted 2009-01

Treatment: Myfortic

All recent trials (11 shown)

CompletedPhase 2

NCT04779957

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Graft nephrectomy is associated with massive allo-sensitization following this event. The occurrence of anti-HLA antibodies is a major barrier to perform a seco…

France18 participantsStarted 2021-10-01

Treatment: Tocilizumab

TerminatedPhase 4

NCT03689075

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of…

United Kingdom35 participantsStarted 2018-11-01

Treatment: Envarsus Oral Product

Allosensitization

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

All recent trials (11 shown)

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

All recent trials (11 shown)

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

Isatuximab in Lung Transplant Recipients

Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Desensitization in Kidney Allograft Using Daratumumab

Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

Alloantibodies in Pediatric Heart Transplantation

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Di…

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers